Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EF2001
- Development stage
- Unknown
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
EF2001 is a **heat-killed preparation of the probiotic bacterium Enterococcus faecalis**, used primarily as a dietary supplement and investigated for metabolic and gut health benefits. Mechanistically, EF2001 modulates lipid metabolism, decreasing lipid accumulation and hepatic steatosis in animal models by activating the **AMP-activated protein kinase (AMPK) pathway** and promoting phosphorylation of acetyl-CoA carboxylase (ACC), while suppressing lipogenic transcription factors such as SREBP-1c and enzymes like fatty acid synthase (FAS) and HMG-CoA reductase. EF2001 also possesses **anti-inflammatory effects** in the gut, reducing the expression of pro-inflammatory cytokines (such as iNOS, COX-2, IFN-γ, IL-1β, IL-6) and mitigating symptoms in mouse models of inflammatory bowel disease. Trials are ongoing to assess its benefits in obese and overweight individuals for gut health and metabolic dysfunction[1][2][3][5].
- Brand names
- EF2001EF-2001EF 2001
- Other names
- Enterococcus faecalis EF-2001heat-killed Enterococcus faecalis EF-2001
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AMPK (Adenosine monophosphate–activated protein kinase)ACC (Acetyl-CoA Carboxylase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)FASN (Fatty acid synthase)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)RELA (Nuclear Factor Kappa B Subunit p65)PPARG (Peroxisome proliferator-activated receptor gamma)SREBP-1 / SREBF1 (SREBP-1)TLR2 (Toll-like Receptor 2)TNFA (Tumor necrosis factor alpha (soluble))XIAPNOS2 (Nitric Oxide Synthase 2)IFNG (Interferon gamma)
Beyond the preview
Go deeper on EF2001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EF2001.